Yorkshire Cancer Research Collaboration

LICTR YCR

The YCR Centre is a Yorkshire-wide collaboration between clinical trialists encompassing statisticians, methodologists, laboratory scientists and clinicians. Together we have a track record of collaborative success in the delivery of early phase clinical research across a broad range of tumour sites and therapeutic interventions, and across a range of research designs (phase I and II trials, feasibility studies, proof of concept studies)

The Centre aims to:

  • Increase access to innovative early phase trials for patients in Yorkshire
  • Increase cancer research funding into Yorkshire
  • Increase collaborations with industry partners
  • Develop the next generation of leading cancer researchers in Yorkshire

Ultimately, the Centre aims to provide more opportunities for Yorkshire-based patients to participate in innovative early phase clinical trials, enabling earlier access to novel therapies and more targeted treatments.

About Yorkshire Cancer Research

Yorkshire Cancer Research is Yorkshire’s very own cancer charity, helping the people of Yorkshire avoid, survive and cope with cancer by funding world-class research. Over 2,000 scientists and clinicians from around the world help us assess and monitor the quality of our research. We are committed to working in partnership with other charities and organisations to achieve the greatest impact in the global fight against cancer.

http://www.yorkshirecancerresearch.org.uk/

Early phase trials

In set-up:

Topic/ Disease Area Acronym Title Research Area
Breast AlphaCAP A randomised phase IB/IIA study of capecitabine plus radium-223 (Xofigo™) in metastatic breast cancer patients with bone metastases Drug Trial
Brain ReoGlio A multicentre, single arm, phase I trial of reovirus/GMCSF in combination with standard of care in adult patients with newly diagnosed glioblastoma Drug Trial

Open:

Topic/ Disease Area Acronym Title Research Area
Bladder
BRAVO
BRAVO: High grade Bladder cancer: A randomised controlled trial of Radical Cystectomy against intra-vesical immunotherapy – A feasibility study
Drug Trial
Metastatic cancer JX594 A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers. Drug Trial

In follow-up:

Topic/ Disease Area Acronym Title Research Area
Lung SABRTooth A study to determine the feasibility and acceptability of conducting a Phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral Stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection. Radiotherapy Trial

Late phase trials

In set-up:

Topic/ Disease Area Acronym Title Research Area
Gastro- intestinal cancer
EMT2
A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases
Drug Trial

Open:

Topic/ Disease Area Acronym Title Research Area
Palliative care Better B A randomised placebo controlled, double blind, feasibility trial of mirtazapine for breathlessness in life-limiting and advanced illness Drug Trial

In follow-up:

Topic/ Disease Area Acronym Title Research Area
Lung SABRTooth A study to determine the feasibility and acceptability of conducting a Phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral Stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection. Radiotherapy Trial